2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

Tenuto-medical

Company Presentations

Thursday, July 23 Company Presentations 4–Israel

Tenuto-medical

Company Info

Name /Tenuto-medical

Address /Kibutz Galuyot 34 Tel Aviv , Israel

Website /www.tenuto-medical.com

Presenter

Name /Ron Striechman

Title /CEO

Email /ron@tenuto-medical.com

Telephone /

Fax /

Mobile /+972-505269871

Company Type

Device,Diagnostics

About the Company

Tenuto brings a completely new approach to early detection of cancer and tumor classification. Our liquid biopsy test analyzes thousands of biochemical changes influenced by the tumor’s presence and expressed in the immune system and plasma.

We are the first to have successfully achieved this by harnessing the power of infrared spectroscopy, applying it to clinical use, and coupling it with our proprietary algorithms and machine learning. The outcome is an accurate and actionable digital biochemical picture that clearly indicates different populations – healthy, benign, and malignant.

Brief Description of main products or services

Our product is a blood test for breast cancer diagnosis (and other indications under development).

 The test is based on Total Biochemical Infrared Analysis (TBIA) of the immune cells and the plasma using infra-red spectroscopy and unique algorithm. The immune system (PBMCs), as well as plasma, are known to be affected by the presence of a tumor at all stages. T cells (and specifically regulatory T cell) as well as B cells, natural killers and platelets, are all participating in identifying or protecting tumor cells at different stages of its development. TM-B2 assay ‘observes’ characteristic biochemical changes in these blood cells and compose a ‘picture’ of cancer patients’ population vs benign and healthy. Plasma, together with PBMCs from the same blood sample, gives additional important relevant information about tumor presence.
While most of the biomarkers assays lean on a single or multiple markers which are known to be directly related to the tumor, TM-B2 ‘observes’ the biochemical composition (e.g. proteins, lipids, nucleic- acids, carbohydrates) of the biological sample and learns patterns in the ‘biochemical picture’ of pre- cancer or cancer patients.

Tenuto medical will provide a complete testing kit to a designated laboratory. The laboratory will then provide the kit to the physician at the location the actual blood screening is conducted. The lab then takes the blood sample and separates its components and the PBMCs and plasma are dried and analyzed by infrared spectrometer. The spectra of the blood components are then analyzed by Tenuto technology – a unique algorithm which is based on multiple clinical trials. The results are sent to the lab and the physician for clinical evaluation.

Contact Person

Name /Ron Striechman

Email /ron@tenuto-medical.com

Phone /